NO144527C - Analogifremg.m. ved fremst. av anti-inflammatorisk virksomme estere av 2-brom-6beta,9alfa-difluor-11beta,16alfa,17alfa,21-tetrahydroksypregna- eller 2-brom-6beta,9alfa-difluor-11beta,17alfa,21-trihydroksypregna-1,4-dien-3,20-dioner - Google Patents
Analogifremg.m. ved fremst. av anti-inflammatorisk virksomme estere av 2-brom-6beta,9alfa-difluor-11beta,16alfa,17alfa,21-tetrahydroksypregna- eller 2-brom-6beta,9alfa-difluor-11beta,17alfa,21-trihydroksypregna-1,4-dien-3,20-dionerInfo
- Publication number
- NO144527C NO144527C NO750633A NO750633A NO144527C NO 144527 C NO144527 C NO 144527C NO 750633 A NO750633 A NO 750633A NO 750633 A NO750633 A NO 750633A NO 144527 C NO144527 C NO 144527C
- Authority
- NO
- Norway
- Prior art keywords
- 9alfa
- 6beta
- 11beta
- difluor
- inflammatorally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8928/74A GB1499822A (en) | 1974-02-27 | 1974-02-27 | 2-bromo-6beta-fluoropregna-1,4-diene-3,20-diones |
| GB2998474 | 1974-07-05 | ||
| GB3294574 | 1974-07-25 | ||
| GB4998274 | 1974-11-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO750633L NO750633L (es) | 1975-08-28 |
| NO144527B NO144527B (no) | 1981-06-09 |
| NO144527C true NO144527C (no) | 1981-09-23 |
Family
ID=27447687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO750633A NO144527C (no) | 1974-02-27 | 1975-02-25 | Analogifremg.m. ved fremst. av anti-inflammatorisk virksomme estere av 2-brom-6beta,9alfa-difluor-11beta,16alfa,17alfa,21-tetrahydroksypregna- eller 2-brom-6beta,9alfa-difluor-11beta,17alfa,21-trihydroksypregna-1,4-dien-3,20-dioner |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5614677B2 (es) |
| AR (1) | AR218601A1 (es) |
| BE (1) | BE826030A (es) |
| CA (1) | CA1064476A (es) |
| CH (1) | CH608243A5 (es) |
| DE (3) | DE2508136C3 (es) |
| DK (1) | DK144068C (es) |
| ES (3) | ES435067A1 (es) |
| FI (1) | FI56188C (es) |
| FR (1) | FR2261776B1 (es) |
| GB (1) | GB1499822A (es) |
| IE (1) | IE42112B1 (es) |
| LU (1) | LU71908A1 (es) |
| NO (1) | NO144527C (es) |
| NZ (1) | NZ176716A (es) |
| RO (1) | RO78881A (es) |
| SE (1) | SE410736B (es) |
| YU (3) | YU108281A (es) |
-
1974
- 1974-02-27 GB GB8928/74A patent/GB1499822A/en not_active Expired
-
1975
- 1975-02-10 CA CA219,681A patent/CA1064476A/en not_active Expired
- 1975-02-14 FR FR7504616A patent/FR2261776B1/fr not_active Expired
- 1975-02-19 DK DK61575A patent/DK144068C/da not_active IP Right Cessation
- 1975-02-20 NZ NZ176716A patent/NZ176716A/xx unknown
- 1975-02-24 AR AR257732A patent/AR218601A1/es active
- 1975-02-24 IE IE379/75A patent/IE42112B1/en unknown
- 1975-02-25 FI FI750537A patent/FI56188C/fi not_active IP Right Cessation
- 1975-02-25 CH CH232575A patent/CH608243A5/xx not_active IP Right Cessation
- 1975-02-25 LU LU71908A patent/LU71908A1/xx unknown
- 1975-02-25 DE DE2508136A patent/DE2508136C3/de not_active Expired
- 1975-02-25 NO NO750633A patent/NO144527C/no unknown
- 1975-02-25 ES ES435067A patent/ES435067A1/es not_active Expired
- 1975-02-26 JP JP2298075A patent/JPS5614677B2/ja not_active Expired
- 1975-02-26 RO RO7581496A patent/RO78881A/ro unknown
- 1975-02-26 SE SE7502146A patent/SE410736B/xx unknown
- 1975-02-26 BE BE153787A patent/BE826030A/xx not_active IP Right Cessation
- 1975-07-25 DE DE2533323A patent/DE2533323C3/de not_active Expired
- 1975-07-25 DE DE2533377A patent/DE2533377C3/de not_active Expired
-
1977
- 1977-02-15 ES ES455933A patent/ES455933A1/es not_active Expired
- 1977-02-15 ES ES455934A patent/ES455934A1/es not_active Expired
-
1981
- 1981-04-27 YU YU01082/81A patent/YU108281A/xx unknown
- 1981-04-27 YU YU01084/81A patent/YU108481A/xx unknown
- 1981-04-27 YU YU01083/81A patent/YU108381A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL7512578A (nl) | Luier of dergelijke. | |
| NO157933C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefemforbindelser. | |
| SE7507437L (sv) | Gascigarrettendare av engangstyp. | |
| SE7506480L (sv) | Sett och anordning for tillverkning av raffinerat, legerat stal. | |
| NL7412230A (nl) | Werkwijze voor de bereiding van organotintri- halogeniden. | |
| AT292929B (de) | Verfahren zur Herstellung von 17α-Monoestern von 11β,17α,21-Trihydroxysteroiden | |
| NL7514696A (nl) | Werkwijze voor de bereiding van nieuwe gesubsti- tueerde propaan-2-ol derivaten en nicotinezure ester daarvan. | |
| NL7608657A (nl) | Bouwelementenstel ter vervaardiging van kast- wanden of dergelijke. | |
| NL178155C (nl) | Wikkelraam voor poolweefsel. | |
| NL184321C (nl) | Werkwijze voor de bereiding van steroiden. | |
| DK129704B (da) | Fremgangsmåde til fremstilling af 17α-klor-6α-fluor-16α-methylpregna-1,4-dien-3,20-dion-21-oler eller estere deraf. | |
| SE7506293L (sv) | Farmaceutiska kompositioner for behandling av hyperkolesterolemi. | |
| NL7511224A (nl) | Werkwijze voor de vervaardiging van elektroband. | |
| DK128352B (da) | Analogifremgangsmåde til fremstilling af 9α-fluor-11β-hydroxypregna-1,4-dien-3,20-dion-[17α,16α-d]-oxazolidinoxaziner. | |
| NL7415287A (nl) | Werkwijze voor het winnen van isopreen. | |
| NL7500148A (nl) | Werkwijze voor de bereiding van onverzadigde len. | |
| DK129039B (da) | Fremgangsmåde til fremstilling af 11β,16α17α21-tetrahydroxy-pregna-1,4-dien-3,20-dioner eller de tilsvarende 16,17-acetonider. | |
| NL7502846A (nl) | Werkwijze voor de bereiding van parasiticiden. | |
| DK134816B (da) | Analogifremgangsmåde til fremstilling af estre af 11beta, 17alfa, 21-trihydroxy-16beta-methylpregna-1,4,8-trien-3,20-dion. | |
| NO144527C (no) | Analogifremg.m. ved fremst. av anti-inflammatorisk virksomme estere av 2-brom-6beta,9alfa-difluor-11beta,16alfa,17alfa,21-tetrahydroksypregna- eller 2-brom-6beta,9alfa-difluor-11beta,17alfa,21-trihydroksypregna-1,4-dien-3,20-dioner | |
| NL7406965A (nl) | Werkwijze voor de winning van ortho-fenylfenol. | |
| NL7416178A (nl) | Werkwijze voor de bereiding van isobutaan. | |
| DK114060B (da) | Fremgangsmåde til fremstilling af terapeutisk virksomme 1,2β-metylensteroider af androstan- eller 9-norandrostanrækken. | |
| SE7508654L (sv) | Forfarande for framstellning av steroider | |
| SE7507482L (sv) | Forfarande for framstellning av substituerade l-sulfonylbensimidazoler. |